Paul Chiu, MD
Interventional Pain Medicine · Alhambra, CANPI 1467440883
Payments from drug & device makers
Across 276 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$833
- Medtronic$736
- Forte Bio-pharma LLC$657
- Curonix LLC$533
- Virtus Pharmaceuticals LLC$334
- Collegium Pharmaceutical, Inc.$314
- plus $3K from 29 others
What the payments were for
- Travel & lodging$4648%
- Food & beverage$5,53592%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 46 | $833 |
| Medtronic | 30 | $736 |
| Forte Bio-pharma LLC | 50 | $657 |
| Curonix LLC | 7 | $533 |
| Virtus Pharmaceuticals LLC | 18 | $334 |
| Collegium Pharmaceutical, Inc. | 14 | $314 |
| Biotronik NRO, Inc. | 6 | $294 |
| Abbott | 12 | $258 |
| Almatica Pharma LLC | 19 | $241 |
| Painteq LLC | 4 | $235 |
| SPR Therapeutics, Inc | 2 | $168 |
| Saluda Medical Americas, Inc. | 6 | $168 |
| Spinal Simplicity, LLC | 8 | $163 |
| Biodelivery Sciences International, Inc. | 8 | $128 |
| Foundation Fusion Solutions, LLC | 3 | $110 |
| Amgen | 6 | $99 |
| Vertex | 4 | $94 |
| Redhill Biopharma Inc. | 5 | $88 |
| Pfizer | 3 | $86 |
| Vertiflex, Inc. | 4 | $75 |
| Bioventus LLC | 2 | $52 |
| Stimwave Technologies Incorporated | 3 | $44 |
| Si-bone, Inc. | 2 | $44 |
| Vertos Medical, Inc. | 1 | $36 |
| Scilex Pharmaceuticals Inc. | 2 | $28 |
| Sentynl Therapeutics, Inc. | 2 | $26 |
| Fidia Pharma USA Inc. | 1 | $24 |
| MML US, Inc. | 1 | $23 |
| Zimmer Biomet | 1 | $22 |
| Avanos Medical | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Nalu Medical, Inc. | 1 | $14 |
| Relievant Medsystems, Inc. | 1 | $12 |
| Nevro Corp. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,007 in reported general payments places this provider in the 65th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levorphanol Tartrate | 17 | $54,560 |
| BelbucaBuprenorphine Hcl | 31 | $30,812 |
| ProlateOxycodone Hcl/Acetaminophen | 11 | $25,407 |
| NalocetOxycodone Hcl/Acetaminophen | 11 | $20,517 |
| Diclofenac Sodium | 38 | $8,678 |
| Buprenorphine | 29 | $7,101 |
| Celecoxib | 81 | $2,601 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 86 | $1,635 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 35 | $1,057 |
| Gabapentin | 105 | $693 |
| Lidocaine | 12 | $536 |
| Oxycodone Hcl | 27 | $535 |
| Naproxen | 150 | $498 |
| Pregabalin | 26 | $460 |
| Baclofen | 17 | $339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $334 | $54,56017 claims |
| Forte Bio-pharma LLCProlate, Nalocet | $657 | $45,92422 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $314 | $30,81231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 188 interventional pain medicine providers in California.
Other interventional pain medicine in Alhambra
- Sheldon JordanSanta Monica$3.1M
- Ezekiel FinkBeverly Hills$2.3M
- Matthew DotyOroville$1.3M
- Tim LeierRancho Mirage$749K
- Pragya GuptaEscondido$647K
- Michael Verdolinla Mesa$563K
- Standiford HelmOrange$476K
- Patrick BuchananCamarillo$453K
- Roy BrownlowSan Diego$452K
- Andrew GermanovichRancho Mirage$408K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.